Eli Lilly also filed lawsuits against compounding pharmacies and medical spas.
Pharmaceutical company Eli Lilly issued a warning in an open letter on Thursday about the dangers of fake and compounded versions of its diabetes and weight loss medications Mounjaro and Zepbound.
Eli Lilly's main competitor, Novo Nordisk, which sells Ozempic and Wegovy, has also filed lawsuits against med spas purportedly selling knockoff versions. In its Thursday open letter, Eli Lilly issued a major warning to consumers, saying the company is "deeply" concerned about the proliferation of online sales of fake versions of its products, and that people should never put products labeled "research purposes only" or "not for human consumption" into their bodies.Fake drugs aside, Eli Lilly is also raising concerns about compounding pharmacies.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly warns about dangers of fake and counterfeit Mounjaro, ZepboundEli Lilly also filed lawsuits against compounding pharmacies and medical spas.
Read more »
Eli Lilly warns about dangers of fake and counterfeit Mounjaro, ZepboundEli Lilly also filed lawsuits against compounding pharmacies and medical spas.
Read more »
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supplyDemand for the drugs Mounjaro and Zepbound has far outpaced supply over the last year, forcing Eli Lilly to invest heavily to scale up its manufacturing.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro. The drugmaker said Friday that it was more than doubling its investment in a site near its Indianapolis headquarters.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Read more »